Difluprednate

Difluprednate
Clinical data
AHFS/Drugs.com Monograph
MedlinePlus a609025
License data
Routes of
administration
topical dermatologic
ATC code D07AC19 (WHO)
Legal status
Legal status
Identifiers
CAS Number 23674-86-4 YesY
PubChem (CID) 32037
DrugBank DB06781 N
ChemSpider 391990 N
UNII S8A06QG2QE N
KEGG D01266 YesY
ChEMBL CHEMBL1201749 N
ECHA InfoCard 100.041.636
Chemical and physical data
Formula C27H34F2O7
Molar mass 508.551
 NYesY (what is this?)  (verify)

Difluprednate is a corticosteroid, It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.

Approval

On June 24, 2008, the US Food and Drug Administration (FDA) approved difluprednate for the treatment of post-operative ocular inflammation and pain.[1] It is marketed by Alcon under the tradename Durezol.

Clinical trials

Difluprednate ophthalmic emulsion 0.05% is also being studied in other ocular inflammatory diseases, including a U.S. Phase 3 study evaluating difluprednate for the treatment of anterior uveitis.[2]

References



This article is issued from Wikipedia - version of the 3/28/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.